Jefferies raises United Therapeutics stock price target on settlement
Jefferies raised its price target for United Therapeutics (UTHR) to $728 from $704, citing a settlement with Liquidia Technologies. The settlement includes a $380.7M payment to UTHR, resolving litigation and preserving its exclusivity in a pulmonary hypertension indication. UTHR's Q2 2026 earnings beat estimates, but revenue fell short. Analysts have mixed views on the stock's valuation.
How this was made
The 30-second read
Why it matters
The cash payment strengthens the balance sheet and removes legal uncertainty, supporting a higher valuation.
Market read
Analyst target raise and settlement cash flow could drive short‑term buying interest in UTHR.
What to watch
Potential future litigation risk and the company's recent revenue miss could temper upside.
Background
United Therapeutics settled a patent infringement case with Liquidia, receiving $380.7M and avoiding an appeal, while analysts adjusted price targets.
Ticker impact
Jefferies raised its price target to $728 after United Therapeutics settled a lawsuit with Liquidia, receiving a $380.7M payment.
upside pressure as investors price in the settlement cash and improved outlook
A $380M settlement for a company with a strong balance sheet and a higher analyst target typically drives buying interest.
Market effects
The settlement may boost confidence in the pulmonary‑hypertension drug sector and could lift peers with similar pipelines.
Limited to U.S. biotech and pharma equities; no broad regional effect.
Minimal global impact beyond the niche therapeutic area.
Counterpoint
The settlement may mask underlying revenue shortfalls; investors should watch for continued sales pressure.
Key entities
- companyUnited Therapeutics Corp.
Biopharma company receiving settlement payment.
- companyLiquidia Technologies
Defendant in the patent lawsuit.
- analyst_firmJefferies
Raised price target to $728.
